Jefferies downgraded Cerevel Therapeutics (CERE) to Hold from Buy with a price target of $45, up from $40, after AbbVie (ABBV) announced plans to acquire Cerevel for $45.00 per share.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CERE: